The November trial date for former SAC Capital Advisors portfolio manager Mathew Martoma has been postponed.
The Associated Press reported that Martoma, who was charged by federal authorities last November for allegedly making over $250 million for SAC Capital using insider information he received regarding an Alzheimer disease drug trial, will now go on trial in January.
U.S. prosecutors filed a revised indictment against Martoma last month, allegedly that he received confidential information from more than 20 doctors.
Martoma has pleaded not guilty to the charges.
Both Connecticut-based SAC and its founder Steve Cohen have been charged with various counts of insider trading. The firm manages about $15 billion in assets.